The drug efflux pump ABCB1 (ATP binding cassette subfamily B member 1) confers chemotherapy resistance in acute myeloid leukemia (AML). We recently identified an ABCB1 enhancer that is activated in response to a range of cellular stressors, including anthracycline chemotherapy. Stress drives increased ABCB1 expression and allows leukemia cells to escape from targeted third-generation ABCB1 inhibition.
|Journal||Molecular & cellular oncology|
|Early online date||8 Jan 2020|
|Publication status||Published - 3 Mar 2020|
Research Beacons, Institutes and Platforms
- Lydia Becker Institute
- Manchester Cancer Research Centre